PIK3CA exon 20 mutations as a potential biomarker for resistance to anti-EGFR monoclonal antibodies in KRAS wild-type metastatic colorectal cancer: a systematic review and meta-analysis
出版年份 2011 全文链接
标题
PIK3CA exon 20 mutations as a potential biomarker for resistance to anti-EGFR monoclonal antibodies in KRAS wild-type metastatic colorectal cancer: a systematic review and meta-analysis
作者
关键词
-
出版物
ANNALS OF ONCOLOGY
Volume 23, Issue 6, Pages 1518-1525
出版商
Oxford University Press (OUP)
发表日期
2011-10-30
DOI
10.1093/annonc/mdr464
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Impact of KRAS, BRAF, PIK3CA Mutations, PTEN, AREG, EREG Expression and Skin Rash in ≥2nd Line Cetuximab-Based Therapy of Colorectal Cancer Patients
- (2011) Zacharenia Saridaki et al. PLoS One
- Markers for EGFR pathway activation as predictor of outcome in metastatic colorectal cancer patients treated with or without cetuximab
- (2010) Jolien Tol et al. EUROPEAN JOURNAL OF CANCER
- Predictive and prognostic value of KRAS mutations in metastatic colorectal cancer patients treated with cetuximab: A meta-analysis of 22 studies
- (2010) Li-Xin Qiu et al. EUROPEAN JOURNAL OF CANCER
- Additional value of EGFR downstream signaling phosphoprotein expression to KRAS status for response to anti-EGFR antibodies in colorectal cancer
- (2010) Geraldine Perkins et al. INTERNATIONAL JOURNAL OF CANCER
- Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis
- (2010) Wendy De Roock et al. LANCET ONCOLOGY
- The importance of KRAS mutations and EGF61A>G polymorphism to the effect of cetuximab and irinotecan in metastatic colorectal cancer
- (2009) K. -L. Garm Spindler et al. ANNALS OF ONCOLOGY
- Prognostic and predictive value of common mutations for treatment response and survival in patients with metastatic colorectal cancer
- (2009) J Souglakos et al. BRITISH JOURNAL OF CANCER
- PIK3CA Mutations in Colorectal Cancer Are Associated with Clinical Resistance to EGFR-Targeted Monoclonal Antibodies
- (2009) A. Sartore-Bianchi et al. CANCER RESEARCH
- PIK3CA Mutations Are Not a Major Determinant of Resistance to the Epidermal Growth Factor Receptor Inhibitor Cetuximab in Metastatic Colorectal Cancer
- (2009) H. Prenen et al. CLINICAL CANCER RESEARCH
- PIK3CA Mutation Associates with Improved Outcome in Breast Cancer
- (2009) K. Kalinsky et al. CLINICAL CANCER RESEARCH
- Multi-Determinants Analysis of Molecular Alterations for Predicting Clinical Benefit to EGFR-Targeted Monoclonal Antibodies in Colorectal Cancer
- (2009) Andrea Sartore-Bianchi et al. PLoS One
- PI3KCA/PTEN deregulation contributes to impaired responses to cetuximab in metastatic colorectal cancer patients
- (2008) F. Perrone et al. ANNALS OF ONCOLOGY
- PIK3CA Exon 20 Mutation is Independently Associated with a Poor Prognosis in Breast Cancer Patients
- (2008) Yuen-Liang Lai et al. ANNALS OF SURGICAL ONCOLOGY
- Primary resistance to cetuximab therapy in EGFR FISH-positive colorectal cancer patients
- (2008) F Cappuzzo et al. BRITISH JOURNAL OF CANCER
- Association of K-ras Mutational Status and Clinical Outcomes in Patients with Metastatic Colorectal Cancer Receiving Panitumumab Alone
- (2008) Daniel J. Freeman et al. Clinical Colorectal Cancer
- KRASMutations As an Independent Prognostic Factor in Patients With Advanced Colorectal Cancer Treated With Cetuximab
- (2008) Astrid Lièvre et al. JOURNAL OF CLINICAL ONCOLOGY
- K-rasMutations and Benefit from Cetuximab in Advanced Colorectal Cancer
- (2008) Christos S. Karapetis et al. NEW ENGLAND JOURNAL OF MEDICINE
- Helical domain and kinase domain mutations in p110 of phosphatidylinositol 3-kinase induce gain of function by different mechanisms
- (2008) L. Zhao et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now